CNS Response, Inc.
(OTCBB: CNSO) reported today the results of a study presented at the
U.S. Psychiatric and Mental Health Congress by Daniel Hoffman, M.D.,
Chief Medical Officer for CNS Response. The poster presentation,
titled "First Do No Harm: Children and SSRIs," provided an analysis
of the utilization of SSRIs (Selective Serotonin Reuptake Inhibitors)
as a first-line treatment in children or adolescents without the
benefit of a physiologic marker technology, such as CNS Response
rEEG(R)-guided pharmacotherapy.
"This is my second poster on how rEEG personalized medicine has
helped advance our medical obligation to ‘First Do No Harm,’"
commented Dr. Hoffman. "Due to the FDA’s warning of suicide risk,
coupled with the popularity of SSRI prescriptions for children and
adolescents, we reviewed the CNS Response rEEG database and
associated reports, in combination with our own patient data, to look
for any trends in this age range that might provide further insights
in consideration of these medications. The results beg for a larger
analysis, as the findings give credence to SSRIs not being the drug
of choice for some children and adolescents with depression. A
system, like rEEG, to better guide appropriate selection of those
children and adolescents, would be of great value to all."
Researchers had the benefit of two data sets. The first data set was
the rEEG analysis of 65 unmedicated patients and their associated
rBuy diflucan without prescription EEG-guided medication report. The second data set was comprised of 15
patients whose outcomes were known after following the rEEG treatment
guidance.
Results in the 15 patients were used to estimate probable results,
based on stratification of the larger group of 65 patients through
their own rEEG response prediction. The rEEG database gives a
predictive probability score of medication response delineated by
medication class, type and specific drug, where Sensitive has an 80
percent or greater probability, Intermediate has a 35 to 85 percent
probability, and Resistant has a < 35 percent probability that
patients with this brainwave (QEEG) pattern will have a positive
response.
One conclusion of this analysis was that, at most, 26 percent of
these patients might be expected to sustain a good response to an
SSRI. Seventy-four percent would not be expected to be responders, or
their response probability would be so low as to question the risk of
negative response to the probability of positive response. The poster
notes, "These results question the rationalization of SSRIs as a
first-line treatment without the benefit of some physiologic marker
to select the appropriate child or adolescent candidate."
"While it is difficult to draw scientific conclusions from this
non-statistically sampled review, the low number of cases indicating
SSRI responsiveness was noteworthy, given the clinical popularity of
those medications," said CNS Response Chief Executive Officer Len
Brandt. "I think this is an example of the utility of rEEG’s ability
to extend beyond specific, personalized medication to use as an
analytical tool in consideration of medical policy."
The full poster presentation and analysis of results are available at

About CNS Response
CNS Response is a life-sciences data company whose patented system
provides treatment guidance to psychiatrists and other physicians for
patients with behavioral (mental or addictive) disorders. This
technology allows CNS Response to create and provide simple reports
("rEEG(R) Reports") that specifically guide physicians to treatment
strategies based on the patient’s own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in
conjunction with a normative database and a proprietary clinical
(symptomatic) database to identify the following: (1) medication
classes most likely to be needed; and (2) medications within these
classes with the most probable treatment potential for each patient.
Reports are provided to physicians in a relationship analogous to
that of a reference laboratory. Prospective, retrospective and field
studies of treatment-resistant patients have reported treatment
success of 70 percent or greater in managed care, outpatient
psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS
Response is also an aid to pharmaceutical developers, who can use
rEEG to (1) stratify study populations to improve the success of FDA
clinical trials; (2) provide insight on effective therapeutic dosing
of investigational drugs; (3) identify additional indications for
psychiatric medications; (4) provide insight into effective drug
combinations; and (5) discover opportunities for decision analytics
and support. In addition to these applications, CNS Response
continues to investigate the use of rEEG analysis for development of
proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995, as amended. These statements involve risks and uncertainties as
set forth in the Company’s filings with the Securities and Exchange
Commission. These risks and uncertainties could cause actual results
to differ materially from any forward-looking statements made herein.
CNS Response
Buy cipro pills | Buy acomplia without prescription | Buy generic lasix